{"nctId":"NCT00421993","briefTitle":"A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris","startDateStruct":{"date":"2006-10"},"conditions":["Acne Vulgaris"],"count":1670,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Adapalene/Benzoyl Peroxide"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Adapalene"]},{"label":"3","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Benzoyl Peroxide"]},{"label":"4","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Topical Gel Vehicle"]}],"interventions":[{"name":"Adapalene/Benzoyl Peroxide","otherNames":[]},{"name":"Adapalene","otherNames":[]},{"name":"Benzoyl Peroxide","otherNames":[]},{"name":"Topical Gel Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A clinical diagnosis of acne vulgaris with facial involvement.\n* A minimum of 20 but not more than 50 Inflammatory lesions\n* A minimum of 30 but not more than 100 Noninflammatory lesions\n* A score of 3 (Moderate) on the Investigator's Global Assessment Scale.\n\nExclusion Criteria:\n\n* More than one acne nodule or any acne cyst.\n* Acne conglobata, acne fulminans, secondary acne, or severe acne.\n* Known previous participation in an Adapalene/Benzoyl Peroxide Topical Gel Trial.\n* Underlying diseases that require the use of interfering topical or systemic therapy.\n* Use of prohibited medications prior to the study unless appropriate washout period is documented\n* Use of hormonal contraceptives solely for control of acne","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Success Rate on the Investigator's Global Assessment","description":"Percentage of subjects rated \"Clear\" and \"Almost Clear\" on 5-point scale (0=clear; 4=severe)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.9","spread":null},{"groupId":"OG001","value":"21.8","spread":null},{"groupId":"OG002","value":"26.7","spread":null},{"groupId":"OG003","value":"17.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Changes in Inflammatory Lesion Counts","description":"Changes in Inflammatory Lesion Counts equals Week 12 Inflammatory Lesion Counts minus Baseline Inflammatory Lesion Counts","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18","spread":null},{"groupId":"OG001","value":"-15","spread":null},{"groupId":"OG002","value":"-16","spread":null},{"groupId":"OG003","value":"-12","spread":null}]}]}]},{"type":"PRIMARY","title":"Changes in Noninflammatory Lesion Counts","description":"Change in Noninflammatory Lesion Counts equals Week 12 Noninflammatory Lesion Count minus Baseline Noninflammatory Lesion Count","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28","spread":null},{"groupId":"OG001","value":"-24","spread":null},{"groupId":"OG002","value":"-23","spread":null},{"groupId":"OG003","value":"-18","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Inflammatory Lesion Counts","description":"Percent Changes in Inflammatory Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-61.7","spread":"33.9"},{"groupId":"OG001","value":"-50.1","spread":"39.4"},{"groupId":"OG002","value":"-52.2","spread":"39.4"},{"groupId":"OG003","value":"-40.8","spread":"41.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Noniflammatory Lesion Counts","description":"Percent Changes in Noninflammatory Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-55.6","spread":"35.3"},{"groupId":"OG001","value":"-46.0","spread":"33.7"},{"groupId":"OG002","value":"-44.1","spread":"37.3"},{"groupId":"OG003","value":"-32.3","spread":"39.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Total Lesion Counts","description":"Percent Changes in Total Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-57.7","spread":"31.9"},{"groupId":"OG001","value":"-47.5","spread":"31.3"},{"groupId":"OG002","value":"-47.2","spread":"32.7"},{"groupId":"OG003","value":"-35.2","spread":"36"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":419},"commonTop":["Dry Skin"]}}}